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Summary
Background Peri-operative chemotherapy and surgery is a standard of care for patients with resectable oesophagogastric 
adenocarcinoma. Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patients responding 
to treatment in advanced gastric cancer. We aimed to assess the safety and efficacy of adding bevacizumab to 
peri-operative chemotherapy in patients with resectable gastric, oesophagogastric junction, or lower oesophageal 
adenocarcinoma. 
Methods In this multicentre, randomised, open-label phase 2–3 trial, we recruited patients aged 18 years and older 
with histologically proven, resectable oesophagogastric adenocarcinoma from 87 UK hospitals and cancer centres. We 
randomly assigned patients 1:1 to receive peri-operative epirubicin, cisplatin, and capecitabine chemotherapy or 
chemotherapy plus bevacizumab, in addition to surgery. Patients in the control group (chemotherapy alone) received 
three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m² 
epirubicin and 60 mg/m² cisplatin on day 1 and 1250 mg/m² oral capecitabine on days 1–21. Patients in the 
investigational group received the same treatment as the control group plus 7·5 mg/kg intravenous bevacizumab on 
day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy, as 
maintenance treatment. Randomisation was done by means of a telephone call to the Medical Research Council 
Clinical Trials Unit, where staff used a computer programme that implemented a minimisation algorithm with a 
random element to establish the allocation for the patient at the point of randomisation. Patients were stratified by 
chemotherapy centre, site of tumour, and tumour stage. The primary outcome for the phase 3 stage of the trial was 
overall survival (defined as the time from randomisation until death from any cause), analysed in the intention-to-treat 
population. Here, we report the primary analysis results of the trial; all patients have completed treatment and the 
required number of primary outcome events has been reached. This study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN 46020948, and with ClinicalTrials.gov, number NCT00450203. 
Findings Between Oct 31, 2007, and March 25, 2014, 1063 patients were enrolled and randomly assigned to receive 
chemotherapy alone (n=533) or chemotherapy plus bevacizumab (n=530). At the time of analysis, 508 deaths were 
recorded (248 in the chemotherapy alone group and 260 in the chemotherapy plus bevacizumab group). 3-year 
overall survival was 50·3% (95% CI 45·5–54·9) in the chemotherapy alone group and 48·1% (43·2–52·7) in the 
chemotherapy plus bevacizumab group (hazard ratio [HR] 1·08, 95% CI 0·91–1·29; p=0·36). Apart from neutropenia 
no other toxic effects were reported at grade 3 or worse severity in more than 10% of patients in either group. Wound 
healing complications were more prevalent in the bevacizumab group, occurring in 53 (12%) patients in this group 
compared with 33 (7%) patients in the chemotherapy alone group. In patients who underwent oesophagogastrectomy, 
post-operative anastomotic leak rates were higher in the chemotherapy plus bevacizumab group (23 [10%] of 233 in 
the chemotherapy alone group vs 52 [24%] of 220 in the chemotherapy plus bevacizumab group); therefore, 
recruitment of patients with lower oesophageal or junctional tumours planned for an oesophagogastric resection 
was stopped towards the end of the trial. Serious adverse events for all patients included anastomotic leaks (30 events 
in chemotherapy alone group vs 69 in the chemotherapy plus bevacizumab group), and infections with normal 
neutrophil count (42 events vs 53).
Interpretation The results of this trial do not provide any evidence for the use of bevacizumab in combination with 
peri-operative epiribicin, cisplatin, and capecitabine chemotherapy for patients with resectable gastric, 
oesophagogastric junction, or lower oesophageal adenocarcinoma. Bevacizumab might also be associated with 
impaired wound healing.
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Introduction
Randomised controlled trials1,2 have shown that the 
addition of peri-operative chemotherapy to surgery 
improves survival for patients with resectable oesophago-
gastric adenocarcinoma compared with surgery alone. 
Despite this increase in survival, mortality in patients with 
this disease remains high, with 5-year overall survival for 
localised disease at diagnosis of only about 40%.3,4
Bevacizumab, a monoclonal antibody that targets VEGF, 
improves responses to chemotherapy and progression-
free survival, but not overall survival, in patients with 
advanced gastric cancer.5,6 In oesophagogastric cancer, a 
complete surgical resection (R0 resection) is an important 
predictor of long-term survival.7 We postulated that a 
higher proportion of patients responding to pre-operative 
chemotherapy would increase the likelihood of an R0 
resection and lead to improved survival outcomes.8 
Therefore, we designed ST03 as a phase 2–3 trial to assess 
the safety and efficacy of adding bevacizumab to peri-
operative chemotherapy for patients with resectable 
oesophagogastric cancer.
The initial phase 2 stage of the trial focused on safety 
and feasibility in the first 200 patients; these results have 
been reported previously.9 The addition of bevacizumab 
was feasible and did not seem to significantly increase 
toxic effects or the likelihood or severity of surgical 
complications. Therefore, the study proceeded to the 
phase 3 stage.
Methods
Study design and participants
We recruited patients aged 18 years and older with 
previously untreated, histologically proven, resectable 
adenocarcinoma of the lower oesophagus, oesophago-
gastric junction, or stomach from 87 UK hospitals and 
cancer centres. The original design (from January, 2007) 
included patients with gastric or Siewert type III 
oesophagogastric junction tumours, with eligibility 
widened in July, 2009, to include type II oesophagogastric 
junction tumours (in response to centres reporting 
diagnostic difficulty in distinguishing between type II and 
III oesophagogastric junction tumours), and further 
widened in March, 2011, to also include type I oesophago-
gastric junction and lower oesophageal tumours (after the 
closure of the Medical Research Council [MRC] OE05 trial 
on Oct 31, 2011), which recruited patients with such 
tumours). Staging investigations included CT scans for all 
patients and endoscopic ultrasound for all lower 
oesophageal and junctional tumours, or according to local 
practice for gastric tumours. Laparoscopy was mandated 
for gastric and type II and III oesophagogastric junction 
tumours, and according to local practice for type I 
oesophagogastric junction and lower oesophageal cancers. 
PET scans, MRI, or bone scans were used when clinically 
indicated according to local practice. To be eligible, 
patients were required to have a WHO performance status 
of 0 or 1 and adequate cardiac, liver, renal, and bone 
marrow function to be eligible. Patients with lower 
oesophageal or oesophagogastric junction tumours also 
had to have adequate respiratory function (FEV1 ≥1·5 L). 
Blood pressure of a maximum of 140/90 mmHg, a left 
ventricular ejection fraction of at least 50%, and the 
absence of proteinuria were also required.
Patients were excluded if they had a medically 
significant co-existing or previous medical condition, 
defined as cerebrovascular disease (transient ischaemic 
Research in context
Evidence before this study
We searched PubMed in April, 2005, for publications relating to 
bevacizumab in oesophagogastric cancer and bevacizumab in 
cancer. In 2006, the MAGIC trial showed an improvement in 
progression-free survival and overall survival when 
peri-operative chemotherapy was given in addition to surgery, 
compared with surgery alone, in patients with resectable 
oesophagogastric adenocarcinoma. In 2011, the AVAGAST trial 
in advanced gastric cancer reported an improvement in tumour 
response and progression-free survival, but not overall survival, 
when bevacizumab was combined with chemotherapy.
Added value of this study
To the best of our knowledge, this trial is the first study in which 
bevacizumab was given to patients with resectable 
oesophagogastric adenocarcinoma in the peri-operative 
setting; the results provide no evidence of a benefit of 
bevacizumab administration in combination with 
peri-operative chemotherapy in these patients. Moreover, the 
safety results indicate that bevacizumab administration might 
also be associated with impaired wound healing.
Implications of all the available evidence
The results of this trial suggest that there is unlikely to be a role 
for bevacizumab in the treatment of localised, operable 
oesophagogastric cancer. The implication of the results is that 
patients given standard perioperative chemotherapy are 
unlikely to benefit from receiving bevacizumab. Future research 
should consider alternative new treatments in combination 
with standard therapy in this patient population.
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attack or stroke), myocardial infarction or angina 
requiring nitrate therapy within the preceding year, 
uncontrolled hypertension, a recent history of any 
gastrointestinal inflammatory disorder or any history of 
uncontrolled hypertension, congestive heart failure (New 
York Heart Association grade 2 or worse), or serious 
cardiac arrhythmia. Those taking corticosteroids or 
undergoing thrombolytic therapy within 10 days before 
starting chemotherapy were also ineligible.
All patients gave written informed consent before 
randomisation. The trial protocol was approved by a 
national ethics committee and the UK Medicines and 
Healthcare products Regulatory Agency. Every partici-
pating centre obtained local approvals.
Randomisation and masking
Eligible patients were randomly assigned (1:1) to receive 
either peri-operative epiribicin, cisplatin, and 
capecitabine chemotherapy or epiribicin, cisplatin, and 
capecitabine plus bevacizumab, in addition to surgery. 
Treatment allocation was done via a telephone call to the 
Medical Research Council Clinical Trials Unit at 
University College London (normally by the research 
nurse at the site who was responsible for following up 
the patient), where trial management staff used a 
computer programme that implemented a minimisation 
algorithm with a random element and stratification by 
chemo therapy centre, site of tumour (lower oesophagus 
vs oesophagogastric junction type I vs type II vs type III vs 
stomach), and tumour stage (according to TNM 6th 
edition). The algorithm established every patient’s 
treatment group allocation at the point of entry (rather 
than through the use of a pre-determined allocation list). 
Patients and investigators were not masked to treatment 
allocation.
Procedures
Epirubicin, cisplatin, and capecitabine chemotherapy was 
given as three pre-operative and three post-operative 
21-day cycles, consisting of 50 mg/m² intravenous 
epirubicin and 60 mg/m² cisplatin on day 1 and 
1250 mg/m² oral capecitabine on days 1–21. Patients in the 
chemotherapy plus bevacizumab group were given 
7·5 mg/kg bevacizumab as a continuous intravenous 
infusion on day 1 of each of the chemotherapy cycles 
(either before or after the chemotherapy was given). To 
maximise any potential treatment effect with an acceptable 
toxicity profile, patients in the bevacizumab group also 
received six further infusions of bevacizumab alone 
(7·5 mg/kg intravenously alone every 21 days) as 
maintenance treatment after post-operative chemotherapy.
No bevacizumab dose reductions were allowed. 
Bevacizumab was discontinued in the event of any new 
case of gastrointestinal perforation, arterial thrombo-
embolic events (including transient ischaemic attack, 
stroke, myocardial infarction, or new diagnosis of 
ischaemic heart disease), grade 3 or 4 haemorrhage, 
grade 3 or 4 congestive heart failure or left ventricular 
dysfunction, grade 4 hypertension, grade 4 proteinuria, 
tracheoesophageal fistula at any grade or any other fistula 
deemed to be possibly related to bevacizumab. These 
events were classified as notable, and subject to expedited 
reporting together with all other toxic effects meeting the 
standard definitions of serious adverse events. Dose 
reductions and interruptions in chemotherapy were 
permitted according to guidance in the trial protocol. All 
serious adverse events were reviewed for categorisation 
and severity by the chief investigator (DC) or trial 
physicians (ECS, AFO).
Surgery was scheduled 5–6 weeks after the last day of 
the final pre-operative chemotherapy cycle; therefore, 
there were at least 8 weeks between the last pre-operative 
bevacizumab administration and surgery. Surgical 
procedures were specified as follows; for gastric or 
Siewert type III oesophagogastric junction tumours 
either proximal, total, or distal subtotal gastrectomy was 
recommended with a lymphadenectomy to include as a 
minimum lymph node stations 1–7 to ensure at least 
15 nodes were excised; for Siewert type II oesophagogastric 
junction tumours, either extended gastrectomy or 
two-phase oesophago-gastrectomy with a two-field 
lymph adenectomy; for Siewert type I oesophagogastric 
junction or lower oesophageal tumours, oesophago-
gastrectomy with either a two phase right thoraco-
abdominal approach or a left thoracoabdominal approach 
with a two field lymphadenectomy. Minimal access 
procedures were allowed only in centres that had 
sufficient experience (at least 20 such procedures done) 
after review of outcomes and complication rates by 
surgeons from the Trial Management Group. Pathological 
evaluation of resected tumour specimens followed 
guidance that was compliant with the Royal College of 
Pathologists’ dataset for oesophagogastric cancer 
resections.
We assessed tumour response to pre-operative 
chemotherapy with Response Evaluation Criteria In Solid 
Tumors (RECIST) criteria (version 1.0; assessed by CT 
scan, with laparoscopy, endoscopic ultrasound, or PET 
scans if clinically indicated) and post-operatively at each 
centre by pathologists who assessed the resected tumour 
specimen to establish the extent of resection, margin 
involvement, extent of lymph node dissection, and 
Mandard tumour regression grade. Resections were 
judged to be curative (R0) if the pathologist considered a 
radical resection had been undertaken and there was no 
evidence of microscopic residual disease with longitudinal 
margins (proximal and distal) microscopically clear and 
there were no viable tumour cells present within 1 mm of 
the oesophageal circumferential resection margins. Post-
operative chemotherapy was started 6–10 weeks after 
surgery. Patients were followed up every 6 months post-
surgery for the first 3 years and every year thereafter until 
death, or at comparable timepoints if treatment was 
discontinued early. Cause of death and disease 
For the protocol see http://www.
ctu.mrc.ac.uk/research/
documents/cancer_protocols/
st03_protocol
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progression events were reported according to local 
investigator assessment.
We assessed quality-of-life data with the European 
Organisation for Research and Treatment of Cancer 
(EORTC) QLQ-C30 and STO22 questionnaires, admin-
istered before and after post-operative chemo therapy 
and twice during the maintenance phase, then every 
6 months post-surgery for 3 years and annually thereafter. 
For patients who were not fit for surgery, quality-of-life 
questionnaires were carried out at similar timepoints. 
Analysis of quality of life will be presented in a separate 
publication. 
We assessed cardiac function by echocardiogram or 
multiple gated acquisition scan at baseline and after pre-
operative and post-operative chemotherapy. After 
completion of the phase 2 stage, left ventricular ejection 
fraction measurements were done only at baseline. 
Before every chemotherapy cycle, a full blood count and 
blood pressure measurements were taken and patients 
were tested for proteinuria. In February, 2010, a protocol 
amendment mandated a nadir neutrophil count on 
day 10 of the first pre-operative chemotherapy cycle 
with granulocyte colony stimulating factor (GCSF) 
recommended for all cases of grade 4 neutropenia, and at 
the investigator’s discretion for grade 3 cases, during all 
subsequent chemotherapy cycles.
Outcomes
For the phase 3 analysis, the primary outcome measure 
was overall survival defined as the time from 
randomisation until death. Secondary outcomes were 
macroscopic disease-free survival, progression-free 
survival, response rates to pre-operative chemotherapy 
Epiribicin, cisplatin, 
and capecitabine 
chemotherapy alone 
(n=533)
Epiribicin, cisplatin, 
and capecitabine 
chemotherapy plus 
bevacizumab 
(n=530)
Sex
Men 425 (80%) 434 (82%)
Women 108 (20%) 96 (18%)
Age (years)
Median (IQR); range 63 (56–68); 31–79 64 (56–69); 28–82
WHO performance status 
0 - Normal activity 381 (71%) 377 (71%)
1 - Restricted in physical 
activity 
152 (29%) 153 (29%)
Pre-treatment tumour site
Lower oesophageal 74 (14%) 70 (13%)
Oesophagogastric 
junction (type I)
62 (12%) 66 (12%)
Oesophagogastric 
junction (type II)
103 (19%) 96 (18%)
Oesophagogastric 
junction (type III)
100 (19%) 109 (21%)
Stomach 194 (36%) 189 (36%)
Pre-treatment tumour staging*
Lower oesophageal, type I or II
2a 42 (8%) 43 (8%)
2b 31 (6%) 31 (6%)
3 157 (29%) 147 (28%)
4a† 3 (<1%) 1 (<1%)
Type II staged as 
gastric/type III‡
6 (1%) 10 (2%)
Gastric and type III
1b 35 (7%) 33 (6%)
2 91 (17%) 95 (18%)
3a 120 (23%) 124 (23%)
3b 28 (5%) 28 (5%)
4§ 20 (4%) 18 (3%)
Patients undergoing PET scans as part of staging
2007–08 5/24 (21%) 4/20 (20%)
2009–10 70/137 (51%) 74/138 (54%)
2011–12 171/263 (65%) 169/259 (65%)
2013–14 81/103 (79%) 82/103 (80%)
(Table 1 continues on next column)
Epiribicin, cisplatin, 
and capecitabine 
chemotherapy alone 
(n=533)
Epiribicin, cisplatin, 
and capecitabine 
chemotherapy plus 
bevacizumab 
(n=530)
(Continued from previous column)
Surgical procedure
Lower oesophageal, type I or II
Oesophago-
gastrectomy
190/239 (79%) 171/232 (74%)
Total gastrectomy 15/239 (6%) 9/232 (4%)
Subtotal gastrectomy 0 0
Distal gastrectomy 1/239 (<1%) 0
Other or unknown 7/239 (3%) 11/232 (5%)
No resection 26/239 (11%) 41/232 (18%)
Gastric and type III oesophagogastric
Oesophago-
gastrectomy
45/294 (15%) 53/298 (18%)
Total gastrectomy 127/294 (43%) 121/298 (41%)
Subtotal gastrectomy 16/294 (5%) 17/298 (6%)
Distal gastrectomy 43/294 (15%) 44/298 (15%)
Other or unknown 13/294 (4%) 12/298 (4%)
No resection 50/294 (17%) 51/298 (17%)
Data are n (%), median (IQR; range), or n/N (%). *Assessed by Tumour Node 
Metastases 6th edition. †Stage 4a patients: T2 N1 M1a (one in the chemotherapy 
alone group); T3 N0–N1 M1a (two in the chemotherapy alone group and one in 
the chemotherapy plus bevacizumab group). ‡These patients were randomly 
assigned after the inclusion of type II oesophagogastric junction tumours but 
before oesophageal tumour staging was added to case report forms and were 
therefore staged under the gastric staging system. §Stage 4 patients: all T4 
N1–N2 M0.
Table 1: Baseline characteristics
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and curative (R0) resection rates. All efficacy analyses 
were done on an intention-to-treat basis.
Disease-free survival was measured from a landmark 
point, taken to be 6 months from randomisation to allow 
for any difference in timing of surgery across all patients, 
to the first occurrence of disease recurrence or death. 
Patients who had an event before the landmark point and 
those who had a macroscopically incomplete (R2) resection 
or no resection were deemed to have had a disease-free 
survival event at time zero. Progression-free survival was 
measured from randomisation to the first occurrence of 
disease recurrence or death; unlike disease-free survival, 
an R2 resection was not considered an event for this 
outcome measure. In all survival analyses, patients who 
had not had the event of interest by the time of analysis 
were censored at the time they were last followed up.
A RECIST response to pre-operative chemotherapy 
was defined for this trial as a partial or complete response. 
Those with stable disease, progressive disease, or who 
had died before the RECIST assessment were regarded 
as non-responders. For the analysis of pathological 
tumour response, a Mandard tumour regression grade of 
1, 2, or 3 was considered a response and in the intention-
to-treat comparison those who did not undergo a 
resection were included as non-responders. 
Sensitivity analysis of overall survival was repeated on 
the following pre-defined baseline subgroups: age 
(<60 years; 60–70 years; >70 years); sex; WHO 
performance status; baseline tumour site; baseline 
tumour stage (separately for gastric/type III oesophago-
gastric junction tumours and type I/II oesophagogastric 
junction/lower oesophageal tumours). We did not do an 
analysis by the type of surgery because this was not 
known at baseline; instead we analysed tumour site as a 
baseline surrogate for this variable.
Statistical analysis
5-year overall survival in the epiribicin, cisplatin, and 
capecitabine chemotherapy alone group was estimated to 
be 40%. This estimate was based on the proportion of 
patients in the peri-operative chemotherapy group of the 
MAGIC trial who were alive at 5 years (36%),1 taking into 
consideration the possible effect of improvements in 
surgical technique, staging, and supportive care over 
time. A 10% improvement in survival would have been 
consistent with the benefit seen when adding 
bevacizumab in other settings at the time the trial was 
designed.10 To detect an absolute 10% improvement in 
5-year survival (corresponding hazard ratio [HR] 0·76), 
with 80% power and a two-sided 5% significance level, 
420 deaths were required. On the assumption that the 
trial would take 3–4 years to complete recruitment, with 
18–24 months’ follow-up, the target sample size was 
estimated to be between 900 and 1100 patients. The trial 
database was frozen for analysis on Sept 30, 2015, after 
the target number of deaths had occurred. The accumu-
lating data were monitored by an Independent Data 
Monitoring Committee (IDMC), which met 13 times 
between May, 2008, and November, 2014, to review safety 
data and efficacy analyses. 
Analyses of survival data were done with the log-rank 
test. Analyses of overall survival, disease-free survival, 
and progression-free survival were based on all randomly 
assigned patients, whereas analysis of overall survival by 
resection status and Mandard tumour regression grade 
were based on all randomly assigned patients with 
available pathological resection status and Mandard 
Figure 1: Trial profile
1063 patients recruited
525 started pre-operative chemotherapy
463 completed three cycles
530 randomly assigned to epirubicin, 
cisplatin, and capecitabine
plus bevacizumab
5 did not start chemotherapy
 2 ineligible
 2 withdrew
 1 diagnosed with a colon lesion
87 had no resection
30 found to be inoperable
13 died before surgery due
16 disease progression
3 comorbidity
2 patient refused surgery
11 other reasons
12 reason unknown
181 had no post-operative 
chemotherapy
72 change in condition or not fit
32 unacceptable toxicity
20 patient choice
15 died before due to start
18 post-operative complications
12 disease progression
5 incomplete resection
7 other or unknown reason
438 underwent a resection
257 started post-operative chemotherapy
197 completed all three cycles
179 started maintenance dosing
 119 received six doses
 27 received five doses
 12 received four doses
 8 received three doses
 5 received two doses
 8 received one dose
529 started pre-operative chemotherapy
472 completed three cycles
533 randomly assigned to epirubicin, 
cisplatin, and capecitabine
4 did not start chemotherapy
 1 ineligible
 1 withdrew
 2 straight to surgery
73 had no resection
21 found to be inoperable
10 died before surgery due
21 disease progression
2 comorbidity
2 patient refused surgery
8 other reasons
9 reason unknown
167 had no post-operative 
chemotherapy
64 change in condition or not fit
32 unacceptable toxicity
22 patient choice
15 died before due to start
12 post-operative complications
9 disease progression
8 incomplete resection
5 other or unknown reason
457 underwent a resection
1 did not start pre-operative
chemotherapy
293 started post-operative chemotherapy
215 completed all three cycles
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tumour regression grade, respectively. We assessed 
consistency of treatment effect across pre-defined 
subgroups with tests for heterogeneity that were based 
on all randomly assigned patients within each subgroup. 
To compare the two groups in terms of the proportions of 
patients responding to chemotherapy and the proportions 
in whom curative resection was achieved, we used the 
χ² test based on all randomly assigned patients who had 
available data from the relevant assessment. Comparison 
of curative resections and pathological responses were 
repeated on only those patients with available data who 
underwent a resection. All analyses were unadjusted for 
covariates and done at a two-sided 5% significance level, 
with no adjustment for multiple comparisons.11 All 
statistical analyses were done with STATA (version 13.0). 
This trial is registered as an International Standard 
Randomised Controlled Trial, number 46020948, and 
with ClinicalTrials.gov, number NCT00450203.  
Role of the funding source
Cancer Research UK reviewed and approved the study 
design. F Hoffmann-La Roche did a factual accuracy 
check on the final article but any decision to incorporate 
comments was made solely at the discretion of the 
authors. Neither funder had any role in the collection, 
analysis, or interpretation of the data. DC, SPS, ECS, SR, 
and REL had access to the raw data. The corresponding 
author had full access to all the data and the final 
responsibility to submit for publication. 
Results
Between Oct 31, 2007, and March 25, 2014, 1063 patients 
were enrolled and randomly assigned to receive 
peri-operative epiribicin, cisplatin, and capecitabine 
chemo therapy (n=533) or peri-operative chemotherapy 
plus bevacizumab (n=530). The baseline characteristics 
were well balanced between the two groups (table 1). The 
median age of all enrolled patients was 63 years 
(IQR 56–68), 859 (81%) of 1063 patients were men, and 
646 (61%) had stage 3 or 4 disease (according to TNM 
6th edition). 144 (14%) had lower oesophageal tumours, 
128 (12%) Siewert type I, 199 (19%) Siewert type II, 
209 (20%) Siewert type III, and 383 (36%) gastric. The 
proportion of patients undergoing PET scanning as part 
of staging has increased steadily during the course of the 
trial (table 1), but did not appear to differ between the 
groups. 
1054 (99%) of 1063 patients (529 in the chemotherapy 
alone group and 525 in the chemotherapy plus 
bevacizumab group) started chemotherapy after random-
isation (figure 1). 472 (89%) of 529 patients in the chemo-
therapy group and 463 (88%) of 525 in the chemo therapy 
plus bevacizumab group who started chemo therapy 
received all three pre-operative cycles. 895 (84%) of 1063 
randomly assigned patients (457 [86%] of 533 in the 
chemotherapy alone group vs 438 [83%] of 530 in the 
chemotherapy plus bevacizumab group) underwent a 
resection in the trial. Figure 1 provides reasons why the 
remaining patients did not undergo surgical resection. 
The median time from the start of the last pre-operative 
cycle to surgery was 62 days (IQR 56–68) in the 
chemotherapy alone group and 62 days (57–69) in the 
chemotherapy plus bevacizumab group. 843 (95%) of 
895 patients had at least 7 weeks between the start of their 
final pre-operative cycle and surgery. 293 (55%) of 
533 patients randomly assigned in the chemotherapy 
group and 257 (48%) of 530 randomly assigned in the 
chemotherapy plus bevacizumab group re-commenced 
chemo therapy post-operatively; 215 (73%) of 293 patients 
in the chemotherapy group and 197 (77%) of 257 patients 
in the chemotherapy and bevacizumab group received all 
three post-operative cycles (figure 1). Of all randomly 
assigned patients, 212 (40%) of 533 in the chemotherapy 
alone group and 195 (37%) of 530 in the chemotherapy 
and bevacizumab group received all six scheduled cycles 
of chemotherapy. Bevacizumab was given in 1407 (94%) 
of 1492 cycles administered pre-operatively and 605 (89%) 
of 679 administered post-operatively. The appendix 
provides further details about pre-operative and post-
operative chemotherapy, including numbers of patients 
who discontinued treatment or had dose reductions 
(appendix pp 4, 5). 
At the time of analysis, we used a reverse Kaplan-Meier 
method to calculate median follow-up, which was 
38·4 months (IQR 27·5–50·8) in the whole population 
and 36·2 months (27·4–51·4) in the chemotherapy alone 
group and 39·1 months (27·6–50·5) in the chemotherapy 
and bevacizumab group. 508 patients died (248 in the 
chemotherapy group and 260 in the chemotherapy and 
bevacizumab group) and 85% of patients in each group 
Figure 2: Kaplan-Meier plot of overall survival
HR=hazard ratio. Patients still alive at the time of analysis were censored at the time they were last followed up. 
Survival curves are unadjusted for covariates and the analysis includes all randomly assigned patients. 
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(451 of 533 given chemotherapy alone and 452 of 530 
given chemotherapy and bevacizumab) had either died 
or been followed up for at least 2 years. 3-year overall 
survival was similar in the two groups: 50·3% (95% CI 
45·5–54·9) in the chemotherapy alone group and 48·1% 
(43·2–52·7) in the chemotherapy and bevacizumab 
group (HR 1·09 in favour of the chemotherapy alone 
group, 95% CI 0·91–1·29; log-rank p=0·36; figure 2). 
Insufficient patients (n=56) had reached the 5-year 
timepoint at the time of analysis to give a reliable 
estimate of 5-year overall survival. 
We recorded 300 disease-free survival events in the 
chemotherapy alone group and 303 in the chemotherapy 
plus bevacizumab group. Disease recurrence was 
confirmed in 210 and 192 patients, respectively (170 and 
159 of whom subsequently died), with the remaining 
events attributable to death before reported recurrence 
(78 in the chemotherapy group and 101 in the chemo-
therapy plus bevacizumab group) and a macro scopically 
incomplete resection (12 vs 10). For progression-free 
survival, a macroscopically incomplete resection was not 
considered an event of interest, so the total number of 
events was therefore 288 in the chemotherapy alone 
group and 293 in the chemotherapy plus bevacizumab 
group. There was no evidence of a treatment effect of 
bevacizumab on either disease-free survival (HR 1·04, 
95% CI 0·89–1·22; p=0·62) or progression-free survival 
(HR 1·05, 95% CI 0·89–1·23; p=0·56).
Analysis of RECIST responses to pre-operative chemo-
therapy (partial or complete response vs stable disease, 
progressive disease, or death before the tumour 
assessment) is based on 875 patients (438 in the 
chemotherapy alone group and 437 in the chemotherapy 
plus bevacizumab group); we excluded 188 patients (95 in 
the chemotherapy alone group and 93 in the 
chemotherapy plus bevacizumab group) with missing 
response data from the pre-operative tumour assessment. 
The proportion of patients responding to treatment 
according to RECIST were similar in the two groups 
(183 [42%] of 438 patients in the chemotherapy group vs 
177 [41%] of 437 in the chemo therapy and bevacizumab 
group; p=0·70). Analysis of pathological tumour 
responses based on Mandard tumour regression grade 
(grade 1–3 vs grade 4–5 or no resection) includes 
895 patients (452 chemotherapy alone, 443 chemotherapy 
plus bevacizumab); those excluded are those who 
underwent a resection but had unavailable pathological 
tumour assessment data. The proportion of patients 
achieving pathological tumour responses were also 
similar between the groups (147 [33%] of 452 patients in 
the chemotherapy alone group vs 135 [30%] of 443 in the 
chemotherapy plus bevacizumab group; p=0·51). 
A repeat of this comparison including only the 727 
patients with available data who underwent a resection 
(376 in the chemotherapy alone group and 351 in the 
chemotherapy plus bevacizumab group) also yielded a 
similar result (147 [39%] of 376 patients in the 
chemotherapy alone group vs 135 [38%] of 351 in the 
chemotherapy plus bevacizumab group; p=0·86).
Comparison of the proportion of resections that 
achieved R0 is based on 1002 patients (505 in the 
Chemotherapy 
alone (n=533)
Chemotherapy plus 
bevacizumab (n=530)
Pre-operative RECIST response
Complete response 21/438 (5%) 11/437 (3%)
Partial response 162/438 (37%) 166/437 (38%)
Stable disease 224/438 (51%) 228/437 (52%)
Progressive disease 21/438 (5%) 21/437 (5%)
Died before assessment 10/438 (2%) 11/437 (3%)
Unavailable 95 93
Extent of resection (pathologist’s assessment)
R0 321/429 (64%) 305/405 (61%)
R1 108/429 (21%) 100/405 (20%)
No resection 76/429 (15%) 92/405 (19%)
Unavailable 28 33
Involved margins*, all resections
R1 108 100
Proximal margin 24 18
Distal margin 17 16
Oesophagogastrectomy only
R1 75 71
At circumferential margin 43 30
Within 1 mm of 
circumferential margin
43 43
Either at or within 1 mm 
of circumferential 
margin†
69 63
Lymph node dissection
<15 nodes 79/432 (18%) 62/406 (15%)
15–24 nodes 146/432 (34%) 137/406 (34%)
≥25 nodes 207/432 (48%) 207/406 (51%)
No resection 76 92
Unavailable 25 32
Mandard tumour regression grade
Grade 1 30/376  (8%) 37/351 (11%)
Grade 2 38/376 (10%) 30/351  (9%)
Grade 3 79/376 (21%) 68/351  (19%)
Grade 4 128/376 (34%) 115/351 (33%)
Grade 5 101/376 (27%) 101/351  (29%)
No resection 76 92
Unavailable 81 87
Data are n or n/N (%). Percentages are based on all patients with non-missing 
data; in the summary of lymph node dissection and Mandard tumour regression 
grade, percentages are based on patients with non-missing data who underwent 
a resection only. *Multiple positive margins for an R1 resection might be 
indicated for a given patient. †Includes those patients in which a viable tumour 
was present either at the circumferential margin or within 1 mm of the 
circumferential margin (the above categories combined). 
Table 2: Surgical and pathological findings
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chemotherapy alone group and 497 in the chemotherapy 
and bevacizumab group); we excluded 61 patients (28 in 
the chemotherapy alone group and 33 in the chemo-
therapy plus bevacizumab group) who underwent a 
resection but had unavailable pathological assessment 
data. Resections were judged to be R0 by local pathologists 
in 321 (64%) of 505 patients in the chemotherapy alone 
group and 305 (61%) of 497 in the chemotherapy plus 
bevacizumab group (p=0·47). When the comparison was 
repeated including only patients who underwent a 
resection (R0 vs R1), the proportions of R0 resections were 
again similar between the groups (321 [75%] of 429 patients 
in the chemotherapy alone group vs 305 [75%] of 405 in 
the chemotherapy plus bevacizumab group). Post-hoc, the 
proportion of R0 resections varied by baseline tumour 
site; gastric tumours had the highest proportion of R0 
resections (265 [87%] of 304 resections), compared with 
type III oesophagogastric junction (117 [75%] of 157), type 
II oesophagogastric junction (106 [72%] of 148), type I 
oesophagogastric junction (62 [61%] of 102), and lower 
oesophageal (76 [66%] of 116). Of 208 R1 resections, 
42 (20%) had a positive proximal margin and 33 (16%) had 
a positive distal margin (table 2). Circumferential margin 
involvement was only reported routinely by the pathologist 
for oesophagogastrectomies; of 146 R1 oesophago-
gastrectomies, 72 (49%) had a positive circumferential 
margin and 132 (90%) were either at or within 1 mm of the 
circumferential margin.
Figure 3 shows the results of pre-defined baseline 
subgroup analyses for overall survival. The results of 
these analyses were generally consistent with the main 
result. Although we did not note any heterogeneity 
overall (I²=0%, p=0·78) or in most subgroups (sex I²=0%, 
p=0·99; WHO performance status I²=0%, p=0·77; 
tumour site I²=0%, p=0·44; gastric tumour stage I²=0%, 
p=0·63; oesophageal tumour stage I²=12%, p=0·29), we 
did note a trend toward heterogeneity across age groups 
(I²=66%; p=0·053). In particular, in patients aged 70 years 
and older, significantly fewer patients who received 
chemo therapy alone died compared with those given 
chemo therapy plus bevacizumab (figure 3). However, in 
this subgroup, the proportion of deaths that were 
reported to be non-disease related was higher in the 
chemotherapy plus bevacizumab group than in the 
chemotherapy alone group (61 [30%] patients given 
chemotherapy and bevacixumab vs seven [19%] of 
36 patients given chemotherapy alone).
Survival beyond the scheduled surgery timepoint 
assesed post-hoc was significantly longer in patients who 
had an R0 resection than in those with an R1 resection or 
no resection (HR 0·23, 95% CI 0·19–0·28; p<0·0001; 
figure 4). Our earlier comparison of the proportion of 
patients achieving a pathological tumour response 
categorised patients with a Mandard tumour regression 
grade of 1, 2, or 3 as responders. However, our data 
suggest that those patients with a Mandard tumour 
regression grade of 1 or 2 might represent a group with 
improved post-operative survival (figure 5). When such 
patients were compared with those with a Mandard 
tumour regression grade of 3, 4, or 5, or no resection 
post-hoc, post-operative survival was significantly better 
(HR 0·30, 95% CI 0·21–0·44; p<0·0001; figure 5).
The frequency and severity of adverse events occurring 
during either pre-operative or post-operative chemo-
therapy were similar between the groups  (table 3, 
table 4). Neutropenia was the most common grade 3 or 
worse adverse event, both pre-operatively (occurring in 
145 [27%] of 529 patients in the chemotherapy alone 
group vs 139 [26%] of 525 patients in the chemotherapy 
plus bevacizumab group) and post-operatively (95 [33%] 
of 292 vs 81 [32%] of 254). This includes two fatal cases of 
Figure 3: Pre-defined baseline subgroup analysis of overall survival
Hazard ratios (HRs) comparing chemotherapy alone with chemotherapy plus bevacizumab in each subgroup are 
plotted against the horizontal axis, with a HR<1 favouring chemotherapy plus bevacizumab. Black squares 
represent the HRs, with their size representing the number of patients in the subgroup concerned. Horizontal lines 
represent 95% CIs for the HRs (arrows indicate that the 95% CI extends beyond the displayed axis range). The 
diamond in the last row is the overall HR; the vertical dashed line is to aid comparison of the overall HR with the 
subgroups. None of the four oesophageal stage IVa patients died, so this subgroup is omitted from this figure. 
16 patients with type II oesophagogastric junction tumours did not have a baseline oesophageal tumour stage and 
are also omitted.  
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infection with neutropenia, one in the chemotherapy 
alone group and one in the chemotherapy plus 
bevacizumab group. Of the 257 patients in the 
chemotherapy plus bevacizumab group who began 
post-operative chemotherapy, 179 (69%) went on to 
receive maintenance bevacizumab and 16 (9%) of these 
179 patients reported a grade 3 or 4 toxicity during 
maintenance treatment, the most common of which 
were neutropenia (four patients), anorexia (3 patients) 
and lethargy (3 patients). The most commonly reported 
serious adverse events were gastrointestinal (60 events 
in the chemotherapy alone group vs 63 in the 
chemotherapy plus bevacizumab group), anastomotic 
leaks (30 events vs 69), and infections with normal 
neutrophil count (42 events vs 53). 
248 patients in the chemotherapy group and 260 in the 
chemotherapy plus bevacizumab group had died at the 
time of analysis. Causes of death were reported to be 
mainly disease-related (204 [82%] of 248 in the 
chemotherapy alone group vs 204 [78%] of 260 in the 
chemotherapy plus bevacizimab group); other deaths 
were due to chemotherapy-related toxic effects (six [2%] vs 
five [2%]), or related to resection or reoperations (13 [5%] 
in each group). Other reasons were given for 58 patients 
(23 [9%] in the chemotherapy group vs 35 [13%] in the 
chemotherapy plus bevacizumab group; appendix) and 
the cause of death was unavailable for the remaining five 
patients (two [<1%] vs three [<1%]). 
30-day post-operative mortality was similar in the two 
groups (14 [3%] of 457 patients who underwent resection 
in the chemotherapy alone group vs 11 [3%] of 438 who 
underwent resection in the chemotherapy and 
bevacizumab group). 21 (5%) of 457 patients in the 
chemo therapy alone group and 22 (5%) of 438 in the 
chemotherapy and bevacizumab group died within 
90 days of surgery. Of the patents who underwent a 
resection, data from the post-operative assessment were 
available for 446 patients in the chemotherapy alone 
group and 427 in the chemotherapy plus bevacizumab 
group. The overall incidence of post-operative compli-
cations was slightly higher in the chemotherapy plus 
bevacizumab group, with 215 (48%) of 446 patients in 
the chemotherapy alone group reporting complications 
com pared with 243 (57%) of 427 patients in the 
chemotherapy plus bevacizumab group. Wound healing 
complications in particular were more prevalent in the 
bevacizumab group, occurring in 53 (12%) patients in 
this group compared with 33 (7%) patients in the 
chemotherapy alone group. However, the overall 
incidence of complications that were deemed to be 
life-threatening was similar in both groups, at 8% (37 of 
446 patients in the chemotherapy alone group and 34 of 
427 in the chemotherapy plus bevacizumab group). 
Appendix p 6 provides full details of the post-operative 
complications.
An increased incidence of post-operative anastomotic 
leak in the chemotherapy plus bevacizumab group became 
apparent towards the end of the trial. At a planned IDMC 
review in June, 2013, leaks were recorded in 30 (10%) of 
312 patients in the chemotherapy group and 48 (16%) of 
297 in the chemotherapy plus bevacizumab group 
(compared with 14 [8%] of 179 and 19 [11%] of 170, 
respectively, at the previous IDMC review in July, 2012). 
Further investigation showed that the increased leak rate 
Figure 5: Kaplan-Meier plot of post-operative survival by Mandard tumour regression grade
HR=hazard ratio. Overall post-operative survival times given by Mandard tumour regression grade, calculated from 
6 months post-randomisation until death (to allow for the difference in timing of surgery between the groups). 
Survival curves are unadjusted for covariates and the analysis includes all patients with non-missing Mandard 
tumour regression grade (168 patients with missing data are excluded). 
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Figure 4: Kaplan-Meier plot of post-operative survival by resection status
HR=hazard ratio. Overall post-operative survival times given by the extent of resection, calculated from 6 months 
post-randomisation until death (to allow for the difference in timing of surgery between the groups). Survival 
curves are unadjusted for covariates and the analysis includes all patients with non-missing resection outcome 
data (61 patients with missing data are excluded). 
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in the bevacizumab group was restricted to those patients 
who underwent oesophagogastrectomy. In June, 2013, 
12 (9%) of 132 patients in this subgroup who received 
chemotherapy alone had post-operative anastomotic leak 
versus 29 (24%) of 123 who received bevacizumab, 
compared with 18 (10%) of 180 versus 19 (11%) of 174, 
respectively, in all other patients. No other relevant clinical 
characteristics were identified that might explain the 
increased frequency of anastomotic leak, nor was there any 
evidence of a centre effect (data not shown). Consequently, 
with 1057 patients randomly assigned, recruitment was 
closed to patients with lower oesophageal or junctional 
Patients given epiribicin, cisplatin, and capecitabine 
chemotherapy alone
Patients given epiribicin, cisplatin, and capecitabine 
chemotherapy plus bevacizumab
Total 
patients
Grade 1–2 Grade 3 Grade 4 Grade 5 Total 
patients
Grade 1–2 Grade 3 Grade 4 Grade 5
Lethargy 529 373 (71%) 40 (8%) 3 (<1%) 0 525 372 (71%) 38 (7%) 3 (<1%) 0
Nausea 529 317 (60%) 36 (7%) 1 (<1%) 0 525 303 (58%) 23 (4%) 0 0
Alopecia 529 324 (61%) 0 0 0 525 328 (62%) 2 (<1%) 0 0
Neutropenia 529 150 (28%) 114 (22%) 30 (6%) 1 (<1%) 525 150 (29%) 105 (20%) 33 (6%) 1 (<1%)
Palmar-plantar 
erythrodysesthesia 
529 173 (33%) 30 (6%) 0 0 525 178 (34%) 30 (6%) 0 0
Stomatitis 529 174 (33%) 10 (2%) 2 (<1%) 0 525 211 (40%) 10 (2%) 0 0
Vomiting 529 169 (32%) 28 (5%) 1 (<1%) 0 525 157 (30%) 18 (3%) 0 0
Loss of taste 529 168 (32%) 1 (<1%) 0 0 525 184 (35%) 0 2 (<1%) 0
Anorexia 529 148 (28%) 18 (3%) 1 (<1%) 0 525 167 (32%) 18 (3%) 0 0
Diarrhoea 529 134 (25%) 24 (5%) 4 (<1%) 0 525 147 (28%) 27 (5%) 1 (<1%) 1 (<1%)
Peripheral neuropathy 529 92 (17%) 3 (<1%) 0 0 525 94 (18%) 0 0 0
Thrombocytopenia 529 61 (12%) 6 (1%) 0 0 525 66 (13%) 3 (<1%) 2 (<1%) 0
Infection (normal 
absolute neutrophil 
count)
529 46 (9%) 6 (1%) 1 (<1%) 0 525 55 (10%) 11 (2%) 0 0
Tinnitus 529 62 (12%) 2 (<1%) 0 0 525 53 (10%) 0 0 0
Hypertension* 477 33 (7%) 0 0 0 468 61 (13%) 4 (<1%) 0 0
Renal toxicity 529 36 (7%) 5 (<1%) 0 1 (<1%) 525 39 (7%) 3 (<1%) 1 (<1%) 1 (<1%)
Infection with 
neutropenia
529 12 (2%) 18 (3%) 11 (2%) 1 (<1%) 525 15 (3%) 23 (4%) 2 (<1%) 2 (<1%)
Liver toxicity 529 26 (5%) 1 (<1%) 0 0 525 23 (4%) 2 (<1%) 0 0
Pulmonary embolism* 477 1 (<1%) 1 (<1%) 17 (4%) 0 468 0 3 (<1%) 18 (4%) 0
Neurotoxicity 529 21 (4%) 2 (<1%) 0 0 525 18 (3%) 1 (<1%) 0 0
Ototoxicity 529 17 (3%) 1 (<1%) 0 0 525 20 (4%) 0 0 0
Chest pain 529 12 (2%) 2 (<1%) 1 (<1%) 0 525 15 (3%) 5 (<1%) 0 0
Deep vein thrombosis* 477 6 (1%) 4 (<1%) 0 0 468 8 (2%) 11 (2%) 1 (<1%) 0
Haemorrhage* 477 5 (1%) 1 (<1%) 1 (<1%) 0 468 13 (3%) 2 (<1%) 0 0
Arrhythmia* 477 8 (2%) 1 (<1%) 0 0 468 4 (<1%) 1 (<1%) 1 (<1%) 0
Other arterial 
thromboembolic events*
477 1 (<1%) 1 (<1%) 0 0 468 2 (<1%) 3 (<1%) 2 (<1%) 2 (<1%)
Other venous 
thromboembolic events*
477 1 (<1%) 0 0 0 468 3 (<1%) 4 (<1%) 2 (<1%) 0
Allergic reaction 529 4 (<1%) 0 0 0 525 4 (<1%) 1 (<1%) 1 (<1%) 0
Myocardial infarction* 477 0 1 (<1%) 2 (<1%) 0 468 0 0 1 (<1%) 1 (<1%)
Cerebrovascular 
accident*
477 0 0 0 0 468 0 2 (<1%) 0 0
Cardiac failure 529 0 1 (<1%) 0 0 525 0 0 0 0
Table shows all grade 1–2 events occurring in at least 10% patients in either group and all grade 3, 4, and 5 events that occurred. Data are n (%). Events graded according to 
Common Terminology Criteria for Adverse Events (version 3.0). After each chemotherapy cycle, patients were asked about the occurrence and severity (grade) of several 
chemotherapy-related toxic effects. These adverse events are presented in order of overall incidence (at any grade), with the most common first. *These toxic effects were 
added to the chemotherapy toxicity assessment case report forms after the trial started and as such, not all participants were asked about these specific toxic effects.
Table 3: Adverse events reported during pre-operative chemotherapy
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tumours planned for an oesophagogastric resection, and 
pre-operative bevacizumab was discontinued in such 
patients who had already been recruited.
At the time of the final analysis (Sept 30, 2015), in 
patients undergoing oesophago-gastrectomy, we recorded 
post-operative anastomotic leaks in 23 (10%) of 
233 patients in the chemotherapy alone group versus 
52 (24%) of 220 in the chemotherapy plus bevacizumab 
group compared with 20 (9%) of 213 and 23 (11%) of 207, 
respectively, in all other patients. Overall, most of the 
103 cases in which onset dates were available occurred 
during the period immediately after surgery (40 [39%] 
within 5 days of surgery and 80 [78%] within 10 days). 
Leak onset dates were provided on serious adverse event 
reports and were therefore not available for 15 cases in 
which the event did not satisfy the criteria for a serious 
adverse event. In those who had an anastomotic leak, 
three (7%) of 43 patients in the chemotherapy alone group 
Patients given epiribicin, cisplatin, and capecitabine 
chemotherapy alone
Patients given epiribicin, cisplatin, and capecitabine 
chemotherapy plus bevacizumab
Total 
patients
Grade 1–2 Grade 3 Grade 4 Grade 5 Total 
patients
Grade 1–2 Grade 3 Grade 4 Grade 5
Lethargy 292 204 (70%) 19 (7%) 0 0 254 176 (69%) 24 (9%) 1 (<1%) 0
Nausea 292 186 (64%) 25 (9%) 0 0 254 150 (59%) 14 (6%) 1 (<1%) 0
Neutropenia 292 63 (22%) 73 (25%) 22 (8%) 0 254 54 (21%) 63 (25%) 18 (7%) 0
Diarrhoea 292 124 (42%) 6 (2%) 0 0 254 105 (41%) 7 (3%) 0 0
Alopecia 292 123 (42%) 0 0 0 254 100 (39%) 0 0 0
Anorexia 292 94 (32%) 12 (4%) 0 0 254 89 (35%) 10 (4%) 0 0
Vomiting 292 95 (33%) 14 (5%) 0 0 254 75 (30%) 13 (5%) 1 (<1%) 0
Loss of taste 292 84 (29%) 0 0 0 254 75 (30%) 0 0 0
Stomatitis 292 56 (19%) 0 0 0 254 68 (27%) 4 (2%) 0 0
Palmar-plantar 
erythrodysesthesia 
292 64 (22%) 3 (1%) 0 0 254 56 (22%) 3 (1%) 0 0
Peripheral neuropathy 292 54 (18%) 1 (<1%) 0 0 254 46 (18%) 0 0 0
Thrombocytopenia 292 24 (8%) 1 (<1%) 0 0 254 32 (13%) 0 0 0
Tinnitus 292 36 (12%) 1 (<1%) 0 0 254 18 (7%) 0 0 0
Infection (normal absolute 
neutrophil count)
292 25 (9%) 3 (1%) 0 0 254 19 (7%) 2 (<1%) 1 (<1%) 0
Proteinuria 273 20 (7%) 1 (<1%) 0 0 237 22 (9%) 0 0 0
Renal toxicity 292 8 (3%) 1 (<1%) 0 0 254 19 (7%) 0 0 0
Infection with neutropenia 292 8 (3%) 7 (2%) 0 0 254 5 (2%) 5 (2%) 1 (<1%) 0
Hypertension* 273 5 (2%) 0 0 0 237 15 (6%) 3 (1%) 0 0
Neurotoxicity 292 7 (2%) 1 (<1%) 0 0 254 7 (3%) 0 0 0
Liver toxicity 292 4 (1%) 1 (<1%) 0 0 254 8 (3%) 0 0 0
Ototoxicity 292 7 (2%) 0 0 0 254 3 (1%) 1 (<1%) 0 0
Reduction in left ventricular 
ejection fraction*
273 4 (1%) 0 0 0 237 4 (2%) 1 (<1%) 0 0
Pulmonary embolism* 273 0 0 5 (2%) 0 237 0 0 3 (1%) 0
Deep vein thrombosis* 273 0 1 (<1%) 0 0 237 3 (1%) 2 (<1%) 0 0
Other venous 
thromboembolic events*
273 2 (<1%) 0 1 (<1%) 0 237 3 (1%) 0 0 0
Haemorrhage* 273 0 1 (<1%) 0 0 237 4 (2%) 0 0 0
Arrhythmia* 273 1 (<1%) 0 0 0 237 2 (<1%) 1 (<1%) 0 0
Chest pain 292 2 (<1%) 0 0 0 254 1 (<1%) 1 (<1%) 0 0
Other arterial 
thromboembolic events*
273 0 2 (<1%) 0 0 237 0 0 1 (<1%) 0
Gastrointestinal perforation* 273 0 1 (<1%) 0 0 237 0 1 (<1%) 0 0
Myocardial infarction* 273 0 0 0 0 237 0 0 1 (<1%) 0
Cardiac failure 292 0 0 0 0 254 0 1 (<1%) 0 0
Data are n (%). Table shows all grade 1–2 events occurring in at least 10% patients in either group and all grade 3, 4, and 5 events that occurred. Events graded according to 
Common Terminology Criteria for Adverse Events (version 3.0). After each chemotherapy cycle, patients were asked about the occurrence and severity (grade) of several 
chemotherapy-related toxic effects. These adverse events are presented in order of overall incidence (at any grade), with the most common first. *These toxic effects were 
added to the chemotherapy toxic effect assessment case report forms after the trial started and as such, not all participants were asked about these specific toxic effects.
Table 4: Adverse events reported during post-operative chemotherapy
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died within 30 days of the operation versus seven (9%) 
of 75 in the chemotherapy plus bevacizumab group and 
revisional operations (appendix) were required in 
22 (51%) of 43 patients in the chemotherapy alone group 
compared with 24 (32%) of 75 in the chemotherapy plus 
bevacizumab group.
Discussion 
The results of our trial show that the addition of 
bevacizumab to peri-operative epiribicin, cisplatin, and 
capecitabine chemotherapy did not improve overall 
survival in patients with potentially resectable 
oesophagogastric adenocarcinoma. There was no clinical 
evidence of a differential biological effect on tumour 
growth; the proportions of patients responding to pre-
operative chemotherapy assessed by both radiological 
RECIST criteria and Mandard tumour regression grade 
from the resected specimen, as well as R0 resection rates, 
were similar in both groups. 
This finding is in contrast to those of one small study 
(n=80), which reported that bevacizumab in combination 
with docetaxel, oxaliplatin, and fluorouracil increased the 
proportion of R0 resections achieved in patients with 
locally advanced gastric cancer,12 and results from studies 
in advanced (unresectable and metastatic) gastric cancer 
in which bevacizumab in combination with cisplatin and 
capecitabine given as first-line treatment increased the 
proportion of patients achieving a response (37·4% vs 
46·0%; p=0·032) and progression-free survival (HR 
0·80; p=0·037) but not overall survival.5 Additionally, 
ramucirumab, a monoclonal antibody against VEGF 
receptor 2, increases median overall survival compared 
with placebo from 3·8 months to 5·2 months as second-
line treatment in advanced disease13 and from 7·4 to 
9·6 months compared with placebo, in combination with 
paclitaxel in the same setting.14 Although an insufficient 
number of patients had reached the 5-year timepoint to 
give a reliable estimate of 5-year overall survival, the 
scarcity of evidence for an effect on tumour growth and 
overall survival to this point suggest that it is unlikely a 
treatment effect would emerge with longer follow-up.
Neoadjuvant bevacizumab has also been assessed in 
other tumour types and has been associated with increased 
clinical and pathological responses;15–17 however, such an 
effect was not evident in the ST03 trial. Most (88%) 
patients in the ST03 trial received 9 weeks of pre-operative 
chemotherapy, which has previously been shown to 
enhance tumour down-staging1 and improve overall 
survival. However, the lack of effect shares similarities 
with results from studies in other tumour types in which 
promising results with bevacizumab in the advanced 
setting have not been replicated in earlier stage disease, 
although these studies were mainly done in the adjuvant 
setting, for example in breast18 and colorectal19,20 cancer.
The finding of an increased anastomotic leak rate in 
patients who had undergone oesophago-gastrectomy was 
unexpected. The trial was designed such that patients 
would have at least 8 weeks between their last pre-
operative infusion of bevacizumab and surgery. This 
period extends well beyond the reported half-life of 
bevacizumab (20 days) and was believed to be sufficient 
to prevent effects on post-operative outcomes. The 
primary outcome measures for the phase 2 component 
were based on tumour perforation rates, cardiac 
assessments, and post-operative complications.11 In the 
phase 2 analysis (n=200; 101 patients in the chemotherapy 
alone group, 99 in the chemotherapy plus bevacizumab 
group), the anastomotic leak rate was 4% in both groups 
(five cases in each group) with 107 (54%) patients having 
gastric tumours, 71 (36%) oesophagogastric junction 
type III, and 22 (11%) oesophagogastric junction type II. 
These figures compare to 275 (32%), 141 (16%), and 
175 (21%), respectively in the subsequent 863 patients, 
with the remainder having oesophagogastric junction 
type I (128 patients) and lower oesophageal (144 patients) 
tumours (recruited after March, 2011). This change in 
eligibility criteria increased the proportion of patients 
undergoing oesophago-gastrectomy, potentially ex-
plaining why the increased leak rate was not apparent 
earlier in the trial.
The treatment of anastomotic leaks varies across the 
UK; however, centres in this study used the same 
treatment irrespective of which group the patient was in. 
Surgeons used omentum for anastomosis coverage 
according to standard practice, although at the time of 
designing the study, randomised data were not available 
to support this practice. In this trial, leak was reported by 
unblinded assessors and clinical, radiological, and 
surgical definitions were all included. Although there is a 
possibility that this method overdiagnosed even small 
(non-clinically significant) leaks, we do not believe that 
this had a differential effect on rates in each group.
Careful review of possible confounding factors including 
centre and laparoscopic surgical approaches did not 
provide any clear explanation for the increased leak rate 
and suggests that there could be a prolonged effect of 
bevacizumab that impairs wound healing. Findings of 
one study21 showed that bevacizumab has sustained effects 
on VEGF inhibition more than 6 weeks after dosing, and 
findings of several rectal cancer trials in which 
bevacizumab was used in conjunction with neoadjuvant 
chemotherapy or chemoradiotherapy showed increased 
rates of post-operative complications.22–25 Tumour and 
blood specimens were collected at baseline in this trial 
and will be used to investigate whether patients susceptible 
to long-term effects of bevacizumab such as impaired 
wound healing can be identified.
The potential limitations of our study were the 
inclusion of both gastric and oesophageal tumours and a 
generous targeted difference of 10% absolute difference 
in survival. However, in our subgroup analysis we 
recorded no indication of a differential effect by tumour 
site, or any evidence of a differential biological effect 
based on R0 resection rates, disease-free survival, or 
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progression-free survival. As with the MAGIC trial1 that 
compared surgery alone with surgery and peri-operative 
chemotherapy, about half of patients (550 [52%] of 1063) 
started post-operative chemotherapy and only 119 (22%) 
of 530 in the chemotherapy plus bevacizumab group 
completed all chemotherapy cycles plus the six cycles of 
maintenance bevacizumab.
Our data are consistent with findings that R0 resection 
is an important predictor of long-term survival. In future 
clinical trials, identification of patients at risk of a positive 
resection margin might have a role in treatment selection; 
careful consideration of the clinicopathological features 
associated with R1 resection will help to inform these 
decisions. The suggestion from these results that a 
Mandard grade of 1 or 2 predicts a better survival outcome 
(as opposed to the usual approach of considering Mandard 
grades 1–3 as a response and grades 4–5 as no response) 
requires further evaluation; however, in this trial, patients 
with a Mandard grade 1 or 2 seem to have improved 
survival compared with those with grade 3. A similar 
survival advantage for Mandard grade 1 and 2 responses 
was seen in the MAGIC trial26 and in the recently reported 
MRC OE05 trial27 in which two cycles of neoadjuvant 
cisplatin and docetaxel, oxaliplatin, and fluorouracil were 
compared against four cycles of neoadjuvant epirubicin, 
cisplatin, and capecitabine for oesophagogastric 
junction and oesophageal adeno carcinoma. However, 
as intensification of chemotherapy in the OE05 trial did 
not lead to improved overall survival for the group of 
patients treated with chemotherapy as a whole, it is 
unclear whether Mandard tumour regression grade 1–2 
(or complete pathological response) is a valid surrogate for 
overall survival as an endpoint in clinical trials.
In conclusion, the addition of bevacizumab to peri-
operative chemotherapy for patients with resectable 
oesophagogastric cancer did not lead to an overall 
survival benefit; therefore these results are not practice 
changing. Ongoing exploration of novel therapies in 
order to improve outcomes for oesophagogastric cancer 
patients is warranted.
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